title: Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4.
abstract: OBJECTIVE
  Egypt has the highest prevalence of HCV worldwide (15%) with a high morbidity and mortality from chronic liver disease, cirrhosis, and hepatocellular carcinoma. The Aim of this study was to investigate the associations between IL-28B single nucleotide polymorphisms (SNP rs12979860) and treatment outcome among Egyptian patients infected with HCV genotype 4.
  
  
  METHODS
  HCV patients were genotyped as CC, CT, or TT at the polymorphic site, rs12979860 in unrelated case control of Egyptian population with HCV.
  
  
  RESULTS
  By using univariate regression analysis, the minor allele of IL28B (p < 0.0001), high serum level of HCV-RNA (p = 0.035), and advanced fibrosis (p = 0.02) were associated with (NRs) (Odds ratio, 3.75 with 95% confidence nterval (2.308-6.1067). While, in multivariate logistic regression analysis, rs12979860 CC genotype was the strongest predictive of SVR (OR = 20.83, 95% CI = 11.63- 37.04, p < 0.0001).
  
  
  CONCLUSIONS
  The IL28B rs12979860 SNP is the strongest predictor of an SVR among Egyptian patients infected with HCV-4.
authors.forename: Mahmoud
authors.initials: M
authors.lastname: El-Bendary
authors.forename: Mustafa A
authors.initials: MA
authors.lastname: Neamatallah
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abd El-Maksoud
authors.forename: Maha
authors.initials: M
authors.lastname: Amin
mesh_terms: D000328:Adult; D000483:Alleles; D000998:Antiviral Agents; D004534:Egypt; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D007378:Interleukins / Q000235:genetics*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D012367:RNA, Viral / Q000097:blood*; D060888:Real-Time Polymerase Chain Reaction; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D012367:RNA, Viral; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda